These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 32636452)

  • 1. Histopathologic features of breast cancer in Li-Fraumeni syndrome.
    Kuba MG; Lester SC; Bowman T; Stokes SM; Taneja KL; Garber JE; Dillon DA
    Mod Pathol; 2021 Mar; 34(3):542-548. PubMed ID: 32636452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort.
    Masciari S; Dillon DA; Rath M; Robson M; Weitzel JN; Balmana J; Gruber SB; Ford JM; Euhus D; Lebensohn A; Telli M; Pochebit SM; Lypas G; Garber JE
    Breast Cancer Res Treat; 2012 Jun; 133(3):1125-30. PubMed ID: 22392042
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic characterization of breast carcinomas in patients with non-BRCA germline mutations: results from a single institution's high-risk population.
    Meiss AE; Thomas M; Modesitt SC; Ring KL; Atkins KA; Mills AM
    Hum Pathol; 2018 Dec; 82():20-31. PubMed ID: 29958926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 as a prognostic factor in breast cancer.
    Ménard S; Fortis S; Castiglioni F; Agresti R; Balsari A
    Oncology; 2001; 61 Suppl 2():67-72. PubMed ID: 11694790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Uncovering the genomic heterogeneity of multifocal breast cancer.
    Desmedt C; Fumagalli D; Pietri E; Zoppoli G; Brown D; Nik-Zainal S; Gundem G; Rothé F; Majjaj S; Garuti A; Carminati E; Loi S; Van Brussel T; Boeckx B; Maetens M; Mudie L; Vincent D; Kheddoumi N; Serra L; Massa I; Ballestrero A; Amadori D; Salgado R; de Wind A; Lambrechts D; Piccart M; Larsimont D; Campbell PJ; Sotiriou C
    J Pathol; 2015 Aug; 236(4):457-66. PubMed ID: 25850943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of TP53 pathogenic variants in early-onset HER2-positive breast cancer.
    Escudeiro C; Pinto C; Vieira J; Peixoto A; Pinto P; Pinheiro M; Santos C; Guerra J; Lisboa S; Santos R; Silva J; Leal C; Coimbra N; Lopes P; Ferreira M; Sousa AB; Teixeira MR
    Fam Cancer; 2021 Jul; 20(3):173-180. PubMed ID: 33051812
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers.
    Thor AD; Moore DH II; Edgerton SM; Kawasaki ES; Reihsaus E; Lynch HT; Marcus JN; Schwartz L; Chen LC; Mayall BH
    J Natl Cancer Inst; 1992 Jun; 84(11):845-55. PubMed ID: 1317462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Microinvasive ductal carcinoma (T1mic) of the breast. The clinicopathological profile and immunohistochemical features of 28 cases.
    Yang M; Moriya T; Oguma M; De La Cruz C; Endoh M; Ishida T; Hirakawa H; Orita Y; Ohuchi N; Sasano H
    Pathol Int; 2003 Jul; 53(7):422-8. PubMed ID: 12828606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer in patients with germline TP53 pathogenic variants have typical tumour characteristics: the Cohort study of TP53 carrier early onset breast cancer (COPE study).
    Packwood K; Martland G; Sommerlad M; Shaw E; Moutasim K; Thomas G; Bateman AC; Jones L; Haywood L; Evans DG; Birch JM; Alsalmi OA; Henderson A; Poplawski N; Eccles DM
    J Pathol Clin Res; 2019 Jul; 5(3):189-198. PubMed ID: 31041842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratin 17 is overexpressed and predicts poor survival in estrogen receptor-negative/human epidermal growth factor receptor-2-negative breast cancer.
    Merkin RD; Vanner EA; Romeiser JL; Shroyer ALW; Escobar-Hoyos LF; Li J; Powers RS; Burke S; Shroyer KR
    Hum Pathol; 2017 Apr; 62():23-32. PubMed ID: 27816721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Case series of Li-Fraumeni syndrome: carcinogenic mechanisms in breast cancer with TP53 pathogenic variant carriers.
    Hosonaga M; Habano E; Arakawa H; Kaneko K; Nakajima T; Hayashi N; Fukada I; Nakamura A; Haruyama Y; Maeda T; Inari H; Kobayashi T; Nakashima E; Ueno T; Takano T; Takahashi S; Ohno S; Ueki A
    Breast Cancer; 2024 Sep; 31(5):988-996. PubMed ID: 39017822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TP53 and CDKN1A mutation analysis in families with Li-Fraumeni and Li-Fraumeni like syndromes.
    Andrade RC; Dos Santos AC; de Aguirre Neto JC; Nevado J; Lapunzina P; Vargas FR
    Fam Cancer; 2017 Apr; 16(2):243-248. PubMed ID: 27714481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis on biological markers in ductal carcinoma in situ of the breast.
    Iwase H; Ando Y; Ichihara S; Toyoshima S; Nakamura T; Karamatsu S; Ito Y; Yamashita H; Toyama T; Omoto Y; Fujii Y; Mitsuyama S; Kobayashi S
    Breast Cancer; 2001; 8(2):98-104. PubMed ID: 11342981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Basal phenotype of ductal carcinoma in situ: recognition and immunohistologic profile.
    Dabbs DJ; Chivukula M; Carter G; Bhargava R
    Mod Pathol; 2006 Nov; 19(11):1506-11. PubMed ID: 16941011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparable frequency of BRCA1, BRCA2 and TP53 germline mutations in a multi-ethnic Asian cohort suggests TP53 screening should be offered together with BRCA1/2 screening to early-onset breast cancer patients.
    Lee DS; Yoon SY; Looi LM; Kang P; Kang IN; Sivanandan K; Ariffin H; Thong MK; Chin KF; Mohd Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Apr; 14(2):R66. PubMed ID: 22507745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of stromal signatures in the tumor microenvironment of ductal carcinoma in situ.
    Sharma M; Beck AH; Webster JA; Espinosa I; Montgomery K; Varma S; van de Rijn M; Jensen KC; West RB
    Breast Cancer Res Treat; 2010 Sep; 123(2):397-404. PubMed ID: 19949854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low risk of invasive lobular carcinoma of the breast in carriers of BRCA1 (hereditary breast and ovarian cancer) and TP53 (Li-Fraumeni syndrome) germline mutations.
    Ditchi Y; Broudin C; El Dakdouki Y; Muller M; Lavaud P; Caron O; Lejri D; Baynes C; Mathieu MC; Salleron J; Benusiglio PR
    Breast J; 2019 Jan; 25(1):16-19. PubMed ID: 30414230
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast carcinoma in sclerosing adenosis: a clinicopathological and immunophenotypical analysis on 206 lesions.
    Yu BH; Tang SX; Xu XL; Cheng YF; Bi R; Shui RH; Tu XY; Lu HF; Zhou XY; Yang WT
    J Clin Pathol; 2018 Jun; 71(6):546-553. PubMed ID: 29436376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Li-Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype-phenotype correlation.
    Sassi H; Meddeb R; Cherif MA; Nasr C; Riahi A; Hannachi S; Belguith N; M'rad R
    BMC Med Genomics; 2022 Mar; 15(1):44. PubMed ID: 35246108
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour markers in breast carcinoma correlate with grade rather than with invasiveness.
    Wärnberg F; Nordgren H; Bergkvist L; Holmberg L
    Br J Cancer; 2001 Sep; 85(6):869-74. PubMed ID: 11556839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.